Drugs / 611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05544591 | Oct 2022 → Jul 2023 | atopic eczema | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05544591 ↗ |
| Action | Inhibit | “thereby inhibiting the signaling of both interleukin (IL)-4 and IL-13” PMID 40057938 ↗ Mar 2025 |
| Modality | Monoclonal antibody | “611, a humanized monoclonal antibody” PMID 40057938 ↗ Mar 2025 |
| Route | Subcutaneous | “subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)” NCT05544591 ↗ |
| Target | IL4R | “611, a humanized monoclonal antibody, selectively targets the interleukin (IL)-4 receptor alpha” PMID 40057938 ↗ Mar 2025 |